CMND Latest Report

Performance of the Current Report

Clearmind Medicine (CMND) recorded a revenue of -RMB1496174 in January 31, 2025, a decrease of 8.83% from -RMB1383991 in January 31, 2024. This result indicates that the Company's revenue performance during the reporting period was poor, and it continued to be in a loss-making state, with the loss widening.

Key Data in the Financial Report

1. The continuous negative revenue indicates that the Company still faces serious challenges in generating revenue and covering costs.

2. Research and development expenses increased significantly, reaching RMB461438 in 2025, up from RMB227478 in 2024, which may put the Company under greater pressure for short-term losses.

3. Marketing, sales, and general and administrative expenses decreased, with RMB1034736 in 2025, down from RMB1156513 in 2024, showing the Company's efforts in controlling costs, but failed to effectively translate into revenue growth.

4. The special items of continuing operating income before income taxes in 2025 reached RMB429880, up from RMB154189 in 2024, which may reflect the Company's positive progress in some non-current projects.

Peer Comparison

1. Overall industry analysis: The industry as a whole may face similar revenue pressure amid economic fluctuations and intensified competition. Insufficient market demand or declining product competitiveness may be the main reason for the general revenue decline.

2. Peer evaluation analysis: CMND's revenue performance is poor compared to other companies in the same industry. It needs to be compared with the revenue situation of other companies in the same industry. If other companies in the same industry generally achieve positive revenue, CMND's market positioning and product strategy may need to be re-evaluated.

Summary

CMND's revenue continues to be negative, and the loss is expanding, mainly due to the significant increase in research and development expenses and the challenges of the overall market environment. Although the Company has made efforts to control operating costs, it has failed to effectively increase revenue, showing its vulnerable position in the competition.

Opportunities

1. CMND is actively preparing for the launch of new products, especially the new drug application in cardiovascular metabolism, which may provide opportunities for future revenue growth.

2. The Company's cooperation development plan with Dr. Glitter Pty Ltd. to launch alcohol alternatives based on MEAI may enhance its market competitiveness.

3. By applying for new patents to strengthen its intellectual property portfolio, the Company can enhance its competitive advantage in the market.

Risks

1. Continuous negative revenue may deteriorate the Company's financial situation and affect its subsequent financing ability.

2. The continuous increase in research and development expenses may exacerbate losses in the short term, while failing to achieve product launch and sales in a timely manner.

3. Intense competition in the market, if new products fail to be launched as scheduled or fail to gain market recognition, may further affect the Company's revenue and growth potential.